Bioregenx (BRGX) Net Income towards Common Stockholders (2022 - 2026)
Bioregenx's (BRGX) quarterly Net Income towards Common Stockholders came in at -$126850.0 in Q1 2026, up 52.46% year-on-year from -$83199.6 in Q1 2025, and up 87.54% quarter-over-quarter from -$1.0 million in Q4 2025.
Bioregenx (BRGX) Net Income towards Common Stockholders (2022 - 2026) Analysis & Trends
Bioregenx's Net Income towards Common Stockholders history runs 5 years deep, the most recent figure standing at -$126850.0 for Q1 2026.
- On a quarterly basis, Net Income towards Common Stockholders rose 52.46% year-over-year to -$126850.0 in Q1 2026; TTM through Mar 2026 was -$1.4 million, a 94.23% increase from a year earlier, with the FY2025 full-year figure at -$3.7 million, up 85.82% from the prior year.
- Net Income towards Common Stockholders rose to -$126850.0 in Q1 2026 per BRGX's latest filing, from -$1.0 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at -$2191.0 in Q3 2022 and bottomed at -$18.2 million in Q4 2024.
- The 5-year median for Net Income towards Common Stockholders is -$178345.0 (2025), against an average of -$1.6 million.
- Across the five-year window, Net Income towards Common Stockholders sank 79554.84% in 2024 and surged 96.87% in 2025, its largest moves.
- Year by year, Net Income towards Common Stockholders stood at -$5535.0 in 2022, then plunged by 12907.52% to -$719966.0 in 2023, then plunged by 2428.49% to -$18.2 million in 2024, then soared by 94.41% to -$1.0 million in 2025, then surged by 87.54% to -$126850.0 in 2026.
- Per Business Quant, the three latest BRGX Net Income towards Common Stockholders figures stand at -$126850.0 (Q1 2026), -$1.0 million (Q4 2025), and -$80565.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Veeva Systems | 32.17 Bn | 24.86 Bn | 662.02 Mn | 260.94 Mn |
| 2 | BrightSpring Health Services | 14.62 Bn | 13.72 Bn | 482.22 Mn | 148.77 Mn |
| 3 | Healthequity | 8.40 Bn | 8.14 Bn | 256.31 Mn | 69.42 Mn |
| 4 | Hinge Health | 5.95 Bn | 5.63 Bn | 154.23 Mn | 34.01 Mn |
| 5 | 10x Genomics | 5.86 Bn | 5.32 Bn | 106.18 Mn | -13.47 Mn |
| 6 | MiniMed | 4.52 Bn | 4.22 Bn | 480.00 Mn | -185.00 Mn |
| 7 | Waystar Holding | 4.46 Bn | 4.40 Bn | 216.84 Mn | 43.28 Mn |
| 8 | Doximity | 3.95 Bn | 3.20 Bn | 125.97 Mn | 19.11 Mn |
| 9 | Privia Health | 3.12 Bn | 2.70 Bn | - | 3.71 Mn |
| 10 | Bioregenx | 9.69 Mn | 9.65 Mn | 348,288.00 | -126,850.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -126,850.00 |
| Dec 31, 2025 | -1.02 Mn |
| Sep 30, 2025 | -80,565.00 |
| Jun 30, 2025 | -178,345.00 |
| Mar 31, 2025 | -266,854.00 |
| Dec 31, 2024 | -18.20 Mn |
| Sep 30, 2024 | -2.58 Mn |
| Jun 30, 2024 | -3.29 Mn |
| Mar 31, 2024 | -704,806.00 |
| Dec 31, 2023 | -719,966.00 |
| Sep 30, 2023 | -3,691.00 |
| Jun 30, 2023 | -4,128.00 |
| Mar 31, 2023 | -229,838.00 |
| Dec 31, 2022 | -5,535.00 |
| Sep 30, 2022 | -2,191.00 |
| Jun 30, 2022 | -33,263.00 |
| Mar 31, 2022 | -37,319.00 |